Page last updated: 2024-10-21

3-aminobenzamide and Medulloblastoma

3-aminobenzamide has been researched along with Medulloblastoma in 1 studies

Medulloblastoma: A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)

Research Excerpts

ExcerptRelevanceReference
"Temozolomide is a DNA-methylating agent used in the treatment of malignant gliomas."1.33Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft. ( Ali-Osman, F; Bigner, DD; Cheng, CL; Dolan, ME; Friedman, HS; Johnson, SP; Keir, ST; Li, H; Modrich, P; Quinn, JA; Salzman, AL; Szabo, C, 2005)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Cheng, CL1
Johnson, SP1
Keir, ST1
Quinn, JA1
Ali-Osman, F1
Szabo, C1
Li, H1
Salzman, AL1
Dolan, ME1
Modrich, P1
Bigner, DD1
Friedman, HS1

Other Studies

1 other study available for 3-aminobenzamide and Medulloblastoma

ArticleYear
Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft.
    Molecular cancer therapeutics, 2005, Volume: 4, Issue:9

    Topics: Animals; Antineoplastic Agents, Alkylating; Base Pair Mismatch; Dacarbazine; DNA Repair; Drug Resist

2005